Dupixent® (dupilumab) sbla for treatment of eosinophilic esophagitis (eoe) in children aged 1 to 11 accepted for fda priority review

If approved, dupixent would be the first and only treatment in the u.s. indicated for children aged 1 to 11 with eoe, a disease driven by type 2 inflammation that impacts the ability to eat

REGN Ratings Summary

REGN Quant Ranking